Matt Segall
From Crucible Network Research Projects
Jump to navigationJump to search
Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new interactive approaches to drug design that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.